{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
NovaBay Pharmaceuticals, Inc.
Is NovaBay Pharmaceuticals, Inc. technically bullish or bearish?
As of June 20, 2025, NovaBay Pharmaceuticals, Inc. is in a mildly bearish trend, indicated by daily moving averages and supported by Bollinger Bands and monthly OBV, despite some mildly bullish signals from the weekly MACD and KST.
Who are in the management team of NovaBay Pharmaceuticals, Inc.?
As of March 2022, the management team of NovaBay Pharmaceuticals, Inc. includes Mr. Paul Freiman (Independent Chairman), Mr. Justin Hall (President and CEO), and directors Mr. Xinzhou Li, Mr. Mijia Wu, Ms. Swan Sit, and Dr. Yenyou Zheng.
What does NovaBay Pharmaceuticals, Inc. do?
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing eye care products, particularly the prescription Avenova for eyelid and lash hygiene. It has a market cap of $3.60 million and reported a net profit loss of $3 million as of March 2025.
How big is NovaBay Pharmaceuticals, Inc.?
As of Jun 18, NovaBay Pharmaceuticals, Inc. has a market capitalization of 3.60 million and reported net sales of 7.15 million with a net profit of -7.44 million over the latest four quarters. Shareholder's funds are at -0.13 million, and total assets amount to 45.91 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
